Queen Mary University Of London

6 trials 3 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

7 Countries active

8 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase II: 4 Phase IV: 2

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rheumatoid arthritis 2

Top IMPs

ATEZOLIZUMAB 2 ABATACEPT 1 AVELUMAB 1 DATOPOTAMAB DERUXTECAN 1 ETANERCEPT 1 IPATASERTIB 1 SARILUMAB 1

All trials

6 total

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab… Pending

2024-516236-10-00 Phase II 2 countries ATEZOLIZUMAB; IPATASERTIB
3TR-PARTNER-RA Recruiting

2024-511470-79-00 Phase IV 5 countries ABATACEPT
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 Phase II 2 countries DATOPOTAMAB DERUXTECAN
The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting

2022-502021-18-00 Phase IV 5 countries ETANERCEPT; SARILUMAB
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel… Ended

2024-518244-20-01 Phase II 2 countries AVELUMAB
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Ended

2024-510750-28-00 Phase II 2 countries ATEZOLIZUMAB

Showing 1–6 of 6 trials

← All sponsors A–Z